China Diabetes Drug Market Overview, 2030

China has one of the highest numbers of diabetes patients globally, with nearly 148 million individuals currently affected. This massive disease burden is spurring increased demand for antidiabetic therapies. The government and healthcare providers are focusing on improving early diagnosis and access to modern treatment options, which is expected to drive the expansion of the therapeutic landscape in the country. In response to this mounting health crisis, China’s government has increased its focus on diabetes management under initiatives like “Healthy China 2030,” aiming to reduce non-communicable diseases through improved prevention, diagnosis, and treatment frameworks. The availability of these advanced drugs has increased with their inclusion in the National Reimbursement Drug List (NRDL), which led to significant price reductions of over 40% through centralized procurement policies. Local pharmaceutical companies are also developing biosimilar versions of GLP-1 and insulin drugs, intensifying competition with global players like Novo Nordisk and Eli Lilly. Meanwhile, DPP-4 and SGLT2 inhibitors continue to see steady growth, especially in urban areas where early detection of diabetes is more prevalent. The diabetes drug market is also seeing a transformation through digital innovation. Mobile health platforms, telemedicine, and smart glucose-monitoring devices are increasingly integrated into diabetes management, enabling better adherence and real-time patient monitoring. Companies are investing in apps that track blood sugar levels, deliver medication reminders, and connect patients with endocrinologists remotely. Additionally, partnerships between domestic pharma and international firms are accelerating R&D for next-generation therapies, including oral insulin and dual-action peptide drugs. China’s National Medical Products Administration (NMPA) has streamlined regulatory approvals for innovative therapies, resulting in a surge of new drug filings and market launches.

According to the research report ""China Diabetes Drug Market Overview, 2030,"" published by Bonafide Research, the China Diabetes Drug market was valued at more than USD 10.98 Billion in 2024. The increasing prevalence of diabetes in China is a primary driver of the diabetes drugs market. A sedentary lifestyle, unhealthy dietary habits, and rising obesity rates contribute significantly to the growing number of diabetic patients. For instance, the International Diabetes Federation reported that China has the largest diabetic population globally, with over 140 million adults living with diabetes. Additionally, the country’s aging population plays a critical role in the surge of diabetes cases, as older individuals are at higher risk of developing type 2 diabetes. With rising healthcare costs, the demand for biosimilar insulin and generic diabetes drugs is increasing in China. Biosimilars provide affordable alternatives to branded biologics while maintaining similar efficacy and safety profiles. For instance, Hangzhou Jiuyuan Gene Engineering has developed Jiyoutai, a biosimilar version of Novo Nordisk’s Ozempic, which has completed late-stage clinical trials and is awaiting regulatory approval. The Chinese government has been actively implementing policies to improve diabetes management and enhance access to treatment. For instance, the inclusion of diabetes drugs in the National Reimbursement Drug List (NRDL) has reduced out-of-pocket expenses for patients, making advanced therapies more accessible. Additionally, government-led initiatives such as the “Healthy China 2030” plan aim to enhance diabetes awareness, early diagnosis, and disease prevention strategies. Regulatory agencies have also streamlined the approval process for innovative diabetes drugs, encouraging pharmaceutical companies to introduce novel treatments in the Chinese market.

Insulin remains a cornerstone of treatment, especially for the vast number of people with type 2 diabetes who progress to insulin dependence and the entire population of type 1 diabetes patients. Domestic companies like Tonghua Dongbao and Gan & Lee, alongside multinationals such as Novo Nordisk and Sanofi, dominate this space. Government-led centralized procurement programs have significantly reduced insulin prices, improving access while reshaping profit margins for manufacturers. GLP-1 receptor agonists, known for their weight loss benefits and cardiovascular protection, are rapidly gaining traction, particularly among urban populations concerned with lifestyle diseases and obesity-related complications. The Chinese government’s focus on innovative therapies is also encouraging more physicians to adopt these newer agents, although pricing remains a challenge for broader adoption in rural regions. DPP-4 inhibitors, such as sitagliptin and linagliptin, maintain strong demand due to their oral formulation, favorable safety profile, and affordability post-generic entry. Their extensive listing in China’s National Reimbursement Drug List (NRDL) further supports their high utilization, particularly in community and secondary hospitals. SGLT2 inhibitors, another rising segment, have gained prominence due to their dual benefits in glycemic control and cardiovascular/renal protection. Drugs like dapagliflozin and empagliflozin are increasingly used in patients with comorbidities such as heart failure or chronic kidney disease, aligning with China's growing burden of such conditions. Other antidiabetic drugs, including metformin, sulfonylureas, and fixed-dose combinations, continue to hold significant market share due to their cost-effectiveness and established efficacy. Metformin remains the first-line therapy and is widely used across all economic segments due to its low cost and high tolerability.

Type 1 diabetes, an autoimmune condition typically diagnosed in children and young adults, accounts for a smaller share of the overall diabetic population in China estimated to be less than 5% of total diabetes cases. However, the burden of Type 1 diabetes is growing due to improved diagnostic infrastructure and rising awareness. Managing Type 1 diabetes necessitates lifelong insulin therapy, making insulin analogs and continuous glucose monitoring (CGM) systems crucial in this segment. Chinese healthcare reforms and a gradual increase in the inclusion of advanced insulin therapies under the National Reimbursement Drug List (NRDL) are supporting the affordability and accessibility of such treatments. Despite being a niche market compared to Type 2, the Type 1 segment has seen increased investment in pediatric endocrinology and the development of smart insulin pens and pumps, especially in tier-1 cities like Beijing and Shanghai. Type 2 diabetes, often associated with aging, obesity, and sedentary lifestyles, dominates the diabetes landscape in China. Oral antidiabetic drugs such as DPP-4 inhibitors, SGLT2 inhibitors, and metformin-based combination therapies are highly prevalent due to their efficacy, safety profiles, and compatibility with China’s evolving public health infrastructure. Moreover, GLP-1 receptor agonists are gaining rapid popularity in urban areas due to their dual benefit of glycemic control and weight loss addressing the needs of the increasing obese diabetic population. Companies are also tapping into the rising consumer preference for once-weekly or oral formulations to enhance compliance.

Oral administration dominates the Chinese market due to its convenience, affordability, and widespread patient acceptance. These oral drugs are not only easy to administer but are also cost-effective, which is a critical factor given China’s vast diabetic population, estimated at around 148 million in 2025, the highest in the world according to the International Diabetes Federation (IDF). The growing burden of diabetes has encouraged the Chinese government to include many oral antidiabetics in the National Reimbursement Drug List (NRDL), further boosting their accessibility and market demand. Subcutaneous administration, typically used for insulin and GLP-1 receptor agonists, also holds a significant and growing share of the market, especially as the prevalence of advanced-stage type 2 diabetes and type 1 diabetes rises. Insulin remains a critical treatment for millions of Chinese patients, especially those with poor glycemic control or long-standing disease. The market for subcutaneous drugs is also being driven by the rising popularity of long-acting and ultra-long-acting insulins, as well as the growing use of GLP-1 RAs such as liraglutide and semaglutide, which offer not only blood sugar control but also weight loss benefits an essential factor considering the rising obesity rates in urban Chinese populations. Intravenous administration is less commonly used in routine diabetes management but remains crucial in acute care settings, particularly for hospitalized patients experiencing diabetic ketoacidosis or severe hyperglycemia. IV insulin is frequently used in intensive care units and emergency scenarios where rapid glycemic control is necessary. China’s modernization of its healthcare infrastructure and rising hospitalization rates due to diabetes-related complications are sustaining this niche demand.

Hospital pharmacies dominate the Chinese diabetes drug distribution landscape, especially for insulin therapies and advanced injectables. Due to the country’s centralized healthcare model, most initial diagnoses, prescriptions, and chronic disease management occur in public hospitals. Chinese patients often rely on tertiary hospitals for diabetes care, particularly in urban areas, where hospital pharmacies serve as the primary point for prescription refills. This channel is vital for insulin-dependent patients, especially Type 1 diabetics, who need cold-chain logistics and professional handling of injectables. The dominance of this segment also stems from strong trust in hospital-based healthcare systems and the inclusion of drugs in national reimbursement lists (NRDL), which patients often access through hospital settings. Online pharmacies have experienced exponential growth, particularly after the COVID-19 pandemic accelerated digital healthcare acceptance. With over 1 billion internet users in China, e-commerce giants like Alibaba Health and JD Health have disrupted the traditional pharmaceutical distribution model by offering prescription drugs, including diabetes medications, via online channels. This is particularly beneficial in rural or semi-urban areas with limited physical access to specialty pharmacies. Retail pharmacies, both chain and independent outlets, are witnessing rapid growth, especially in Tier 2 and Tier 3 cities. This segment serves as a convenient follow-up channel for patients with stable conditions, especially those on oral hypoglycemic agents like metformin or DPP-4 inhibitors. The retail segment is also seeing higher adoption among middle-aged and elderly consumers seeking easier access and frequent drug purchases. The Chinese government's emphasis on ""dual-channel"" drug procurement has helped retail pharmacies grow by enabling them to dispense reimbursable drugs previously restricted to hospitals.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Diabetic Drug Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Insulin
• GLP-1 Receptor Agonists
• DPP-4 Inhibitors
• SGLT2 Inhibitors
• Others (metformin, sulfonylureas, and combination therapies)

By Diabetes
• Type-1
• Type-2

By Route of Administration
• Oral
• Subcutaneous
• Intravenous

By Distribution Channel
• Hospital Pharmacies
• Retail pharmacies
• Online Pharmacies Show more